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The study presented is a comprehensive overview of commercial parenteral protein 
formulations, approved by the European Medicines Agency (EMA), 1995-2018. The 
objective of this overview was to analyse current trends in the design of commercial 
parenteral protein products and thereby support formulation scientists in the design of 
new formulations. 
The main data source was the publicly available European Public Assessment Reports 
(EPARs) published by the EMA for each authorised product. An analysis of the 
percentage of formulations in a liquid and lyophilised form was conducted. In 
addition, the number of products containing individual excipients, classified into 
functional categories is provided. Finally, the overview includes comprehensive 
details of product compositions obtained from EMA, US Food and Drug 
Administration (FDA) and product Marketing Authorisation Holder. 
Data analysis highlighted trends in the number of products approved, and the higher 
percentage of liquid parenteral protein formulations (66%) compared to lyophilised 
formulations (34%). This overview identifies the most commonly incorporated 
excipients employed as buffering agents, stabilisers/bulking agents, surfactants, 
preservatives and tonicifiers, including their concentration ranges of use in both liquid 
and lyophilised formulation approaches. Finally, antibody-based formulations were a 
particular focus of this overview. The relationship between parenteral routes of 
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The focus of parenteral protein formulation design is to identify an excipient 
composition that will stabilise proteins against stresses experienced during 
processing, storage, and administration. Excipients also aid reconstitution of 
lyophilised formulations, maintain sterility of multi-dose products, provide 
isotonicity, and in a small number of cases alter pharmacokinetics (1, 2). The majority 
of parenteral protein formulations consist of proteins and excipients in an aqueous-
based solution or suspension. Processing conditions and external factors such as shifts 
in pH, changes in temperature, surface interactions and extraneous impurities can 
destabilise proteins, provoking their chemical and physical structural degradation (3, 
4). In some cases, aqueous formulations of therapeutic proteins do not provide 
adequate stability and therefore, a dried state formulation is a favoured, alternative 
approach which can aid the stability and prolong the shelf-life of protein products (5). 
Lyophilisation, the process of subliming water from frozen solutions under low 
pressure (vacuum), is a widely employed technique for the manufacture of dried 
biological materials (6). However, lyophilisation has the potential to cause protein 
damage due to stresses during both the freezing and drying phases (3, 7). Hence, an 
appropriate excipient composition is required to protect proteins from stresses 
experienced during the lyophilisation process. 
The function and behaviour of excipients in protein formulations is widely reported 
(8-14). Despite the wide range of formulation information available, it can be 
challenging for a formulation scientist to get an overview of how frequently 
excipients are included in commercial protein products. For example, prior 
publications focus on the function of excipients and provide a range of products as 
examples of their application. What differentiates this overview from previous work 
is that it builds on earlier literature and provides up to date, comprehensive 
information of the frequency of excipients use in approved protein products. It also 
presents an analysis of the quantitative excipient composition in the majority of the 
commercial protein products. The compilation of such information creates a valuable 
source for formulation scientists regarding the regulatory acceptance of excipients and 
their prior history in commercial formulations.  
Approval of therapeutic protein products for use within the European Union is via a 
centralised procedure (15). The European Medicines Agency (EMA) publishes a 




or refused), providing the public with information regarding the product. The EPAR 
is not a single document but a resource containing a set of regulatory documents 
related to authorisation details, product information and assessment history. The 
EPAR is one of the most informative and up to date public sources of information on 
a large number of commercial therapeutic proteins. The overview presented is a 
summary of the wealth of the formulation data available in the EPARs in relation to 
approved parenteral protein formulations. Specifically, data was gathered and 
analysed to provide a breakdown of products according to protein type, formulation 
approach (aqueous-based liquid or lyophilised formulations), the most frequently 
included excipients classified in functional categories, with a more detailed look at 
antibody formulations.  
In reviewing EPARs’ data, the split of protein formulations between the liquid and 
dried (lyophilised) state was investigated and the types of excipients incorporated in 
both formulation approaches (liquid or lyophilised) are discussed. Qualitative and 
quantitative composition of protein formulations can be influenced by the process 
selected for manufacturing products in a certain dosage form (liquid or lyophilised). 
The overview provides details of the excipient concentrations employed in approved 
protein products in the European Union (EMA). Due to the limited data related to the 
excipient quantitative composition in the EPARs, this information has been 
supplemented by using FDA sources (16) and product information documents 
published by the Marketing Authorisation Holder (17). The excipient quantitative 
composition is provided for 215 out of 264 protein products and 88 out of 94 antibody 
products approved in the European Union. 
The final part of the overview focuses specifically on monoclonal antibody (Mab) 
products, since Mabs are currently the largest class of therapeutic proteins (18-21). 
Mab doses required for the treatment of chronic diseases are relatively high (usually 
50-200 mg) compared to the majority of the other therapeutic proteins (22). 
Intravenous infusion administration is mostly used for the delivery of a number of 
these products. However, an alternate treatment approach is to formulate Mabs at high 
concentrations to enable administration of the required dose in smaller volumes (1-2 
ml) subcutaneously (SC). Employing this approach can avoid intravenous infusions 
and allow patients to be treated at home rather than in a hospital setting. However, the 
formulation of proteins in high concentrations represents a challenge (20, 23-27). 




have the potential to stimulate an immune-response following administration (24-26). 
Furthermore, high concentration protein formulations can be challenging to lyophilise 
due to the high total solute concentration, which can prolong the reconstitution time 
of lyophilised products and increase the viscosity of liquid and reconstituted 
formulations (23, 24, 27). Therefore, the selection of appropriate excipient 
compositions is required to address these challenges when designing high 
concentration protein formulations (21, 23).  
 
2. Methodology 
A review of the EPARs available on the EMA website was conducted for all 
parenteral protein products authorised centrally in the European Union between 1995-
2018 (up to June 2018) (22). For each of these products, the following information 
was collected: commercial name, active pharmaceutical ingredient (API) and related 
quantitative composition, class of therapeutic protein, therapeutic area, dosage form, 
route of administration, excipient composition, date of issue of marketing 
authorisation and marketing authorisation holder (pharmaceutical company). 
Information was compiled in an MS Excel database (included in supplementary 
information). The accuracy of data transferred to the database was assured by two 
researchers checking 100% of the data entries against the EPARs.  
Formulations were divided into two groups: liquid (L) and lyophilised (LYO), based 
on their manufacturing process detailed in the EPARs. Commercial products having 
the same name but different excipient composition, different formulation approaches 
(e.g. liquid versus lyophilised) or a different liquid formulations’ format (e.g. 
concentrate, solution or suspension) were considered as distinct products in this 
overview. 
All excipients were categorised considering their potential roles in protein 
formulations and were assigned to one of seven functional categories. In the case of 
multi-functional excipients, they were listed in one category but referred to in the 
discussion under all relevant categories. Excipients can possess diverse roles when 
added at different concentrations or to different formulation approaches. This multi-
functional nature of excipients influenced their classification in this publication. For 
example, amino-acids were designated as a single category with a range of functions 




category comprise excipients (mainly carbohydrates) that in the liquid dosage form 
serve as stabilisers. However, some of these excipients in the lyophilised dosage form, 
have the potential to act also as bulking agents. Furthermore, as formulation data does 
not specify the excipients’ solid form (amorphous or crystalline) it was not possible to 
separate the stabilising and bulking functions of some excipients (amino acids and 
carbohydrates) in lyophilised formulations. Therefore, the following seven categories 
were designated 1) non-amino acids buffers 2) amino acids buffers/stabilisers/bulking 
agents; 3) non-amino acids stabilisers/bulking agents; 4) surfactants; 5) preservatives; 
6) tonicifiers and 7) other excipients.  
The ‘other excipients’ category consisted of excipients present in a relatively low 
number of products, this included complexing agents, antioxidants, solubilising 
agents and excipients exclusively present in specific types of formulations, for 
example zinc salts in insulin products. The hypothesis and assumptions regarding the 
role of these excipients in a specific product were stated only in presence of available 
information (16, 22, 28-30) or individual specific references which are detailed in 
section 3.2.8.  
The analysis of the percentage and frequency at which individual excipients were 
included in the products was conducted using IBM SPSS Statistics v.23 software. 
Percentage of products containing a specific excipient or excipient category is 
calculated as percentage within the type of dosage form (liquid or lyophilised). 
Quantitative composition of protein products is also reported in this overview as a 
guideline for the range of protein and excipients concentrations employed in marketed 
formulations. This information was gathered from accredited sources: FDA label 
(FDA) (16) and product information document (Marketing Authorisation Holder) 
(17), when data was not provided in the EPAR’s scientific discussion (Assessment 
history, EMA) (28). These primary information sources are dynamic databases; hence 
this overview is a snapshot of the marketed products information available in the 
specific timeframe. Furthermore, to guarantee accuracy of the dataset, only 
information that could be verified against the primary sources was included in this 
overview. Again, the accuracy of data transferred was assured by two researchers 
checking 100% of the products’ information against these sources. It is important to 
note that information listed in this overview relates only to products approved by the 




jurisdictions, for example, products with different strengths or excipient 
compositions. 
Analysis of monoclonal antibody products was also conducted to show the 
relationship between concentration of protein administered and route of delivery.  
 
3. Results and discussion 
3.1  Approved protein formulations 
EPAR data showed that approximately 440 parenteral products were approved by the 
EMA via its centralised procedure in the period 1995-2018 (June). More than half of 
these products (n=264) contained therapeutic proteins and a greater number of them 
were formulated as liquid dosage forms (66%; n=174), compared to lyophilised forms 
(34%; n=90). Figure 1 shows that the number of liquid parenteral protein 
formulations is consistently higher than the number of lyophilised formulations 
approved in the timeframe studied. Since 2013, approximately 20 parenteral protein 
products have been approved per year. 
Therapeutic proteins included in liquid and lyophilised products, were divided into 
their functional classes, Figure 2a and 2b. Antibodies (36%; n=94) and hormones 
(27%; n=71), represent the two main classes, and are more commonly formulated as 
liquid formulations (antibodies: n=69 and hormones: n=61) compared to lyophilised 
formulations (antibodies: n=25 and hormones: n=10). Insulin and its analogues are the 
most frequent therapeutics in the class of hormone products (n=26 out of 61), and 
they are formulated exclusively as liquid dosage forms (solutions for infusion or 
injection, and suspensions for injection). In contrast, coagulation factors are 
manufactured only as lyophilised formulations (n=24) and represent the second 
largest class of therapeutic proteins in this dosage form following antibodies. 
 
3.2  Excipients included in approved protein formulations  
3.2.1 Excipient categories 
Excipients were subdivided into seven categories: non-amino acids buffers; amino-
acids buffers/stabilisers/bulking agents; non-amino acids stabilisers/bulking agents; 
surfactants; preservatives; tonicifiers and other excipients as detailed in section 2. The 
percentages of liquid and lyophilised products containing excipients which fall into 




frequently employed in both liquid and lyophilised products, whereas others, such as 
preservatives, are more specific to one formulation approach (e.g. multi-dose liquid 
formulations). 
The majority of the formulations: liquid (70%; n=122) and lyophilised (61%; n=55) 
contain non-amino acids buffers. However, amino acids are present in a large number 
of products (L: 39%; n=68; LYO: 51%; n=46) and can have different functions as 
buffering agents or stabilisers/bulking agents depending on the concentration 
incorporated. A small number of products are formulated in the absence of buffering 
agents. This may be due to the ability of the protein to maintain the critical pH, 
especially if formulated at high concentrations (e.g. FLEBOGAMMA DIF
® 
(human 
normal immunoglobulin)) (31).  
Non-amino acids stabilisers are present in a large number of liquid products (64%, 
n=111). Excipients included in the non-amino acids stabilisers/bulking agents 
category are also incorporated in most of the lyophilised products (93%, n=84). 
Surfactants are present in a similar percentage of liquid (65%; n=113) and lyophilised 
(62%; n=56) formulations. Preservatives are included in liquid (29%, n=50) and 
lyophilised (6%, n=5) products. As expected, all multi-dose products (n=53) contain 
preservatives. Multi-dose products comprise 20% of all products (liquid and 
lyophilised) and are more commonly formulated in the liquid dosage form (n=48). All 
lyophilised formulations intended for multiple use contain preservatives in the diluent 
for reconstitution and none in the lyophilised product. The reason for including 
preservatives directly in the diluent for reconstitution is to minimise any possible 
preservative-protein interactions (4, 32). Antibodies are exclusively formulated in a 
single dosage form, whereas insulin in a multiple dosage form. Tonicifiers are 
incorporated in a high percentage of both liquid (36%; n=62) and lyophilised (42%; 
n=38) formulations to achieve the iso-osmolarity recommendations for parenteral 
administration (33-35). Excipients classified in the ‘other excipients’ category were 
present in a similar percentage of liquid (27%; n=47) and lyophilised (22%; n=20) 
products.  
Table I. summarises the more common excipients included in liquid and lyophilised 
products for each functional category. This table also presents the concentration 
ranges employed for each of these excipients in the liquid and lyophilised protein 
products analysed. Non-amino acids buffers are usually included in a range of 






 (antithrombin alfa) contains sodium citrate at a higher 
concentration of 135 mM (34.8 mg/ml). Amino acids can have different functions; 
hence they can be used in a wide range of concentrations (0.1 and 52 mg/ml) within 
the formulations. The usual range of concentrations at which amino acids are 
employed is between 0.1-25 mg/ml, with an ionic strength of 5-260 mM. However, 
arginine is added in higher concentrations compared to other amino acids, acting 
mainly as a stabiliser. For example, METALYSE
® 
(tenecteplase) contains arginine at 
a concentration of 52 mg/ml to increase the solubility of the protein as reported in the 
product EPAR’s scientific discussion (36). Histidine at low concentrations between 
0.7-8.9 mg/ml is included in the majority of the products, serving mainly as a buffer. 
Histidine and arginine are frequently used in their hydrochloride salt form in protein 
products. Glycine is often employed as a stabiliser/bulking agent besides its role as a 
buffering agent at concentrations between 0.1-25 mg/ml; whereas methionine at low 
concentrations (0.06-3 mg/ml) is usually selected for its antioxidant properties. Non-
amino acids stabilisers and bulking agents are incorporated at concentrations up to 
200 mg/ml to maintain the required molar ratio with the protein. Surfactants are 
generally present in a different range of concentrations in liquid (0.01-2 mg/ml) and 
lyophilised (0.04-1.2 mg/ml) products. However, the liquid formulation ORENCIA
®
 
(abatacept), with a high concentration of the fusion protein (125 mg/ml), contains 8 
mg/ml of Poloxamer 188. Preservatives are employed in concentrations between 0.7 
and 14.9 mg/ml. Sodium chloride and potassium chloride are included as tonicifiers 
and/or stabilisers in a variable range of concentrations between 0.2 to 27 mg/ml. 
 
The following sections provide greater details and discussions regarding individual 
excipients divided into each functional category. 
 
3.2.2 Non-amino acids buffers 
Buffers are required to adjust and maintain the pH to a value at which the specific 
protein has maximal stability. The optimum pH value is selected considering the 
protein’s isoelectric point (pI) as a critical physical parameter that can affect protein 
solubility, aggregation and degradation (37). Furthermore, the selected pH needs to be 
in a physiological range in order to avoid irritation, pain or extravasation during 
injection into the patients. For intramuscular and subcutaneous administration the 




reported, the values range from pH 3.1 for JETREA
® 
(ocriplasmin) to pH 8.15 for 
XULTOPHY
® 
(insulin degludec), which are respectively administered through 
intravitreal and subcutaneous routes. 
The percentage of approved liquid and lyophilised parenteral products containing 
non-amino acids buffers are shown in Figure 4. The most common buffers (excluding 
amino acids) employed in liquid protein formulations are: sodium phosphate (33%; 
n=58), sodium acetate (19%; n=33) and sodium citrate (17%; n=29). Sodium 
phosphate (32%, n=29), and sodium citrate (20%; n=18) are also frequently added to 
lyophilised protein products (12). However, acetate buffer was found not to be 
incorporated in any lyophilised products identified as part of this overview. Acetic 
acid is volatile and can be converted to a gaseous state and hence be lost from the 
formulation during lyophilisation (39, 40). Sodium phosphate buffers employed in 
commercial products are usually composed of two salt forms: sodium dihydrogen 
monohydrate and disodium dihydrate. The different sodium phosphate components 
were grouped together under the name of sodium phosphate in this overview. 
Despite their wide use as buffers, sodium phosphate salts present some drawbacks, 
especially when included in formulations intended to be lyophilised. Highly 
concentrated buffer systems can crystallize and provoke changes in pH during 
freezing (39). Sodium phosphate is prone to crystallize during freezing, leading to a 
pH shift of up to four units. Furthermore, sodium phosphate crystallization and 
precipitation are severely influenced by salt components solubility and concentration, 
temperature, cooling rate, volume of solution and initial pH value (41, 42). The 
presence of other compounds can influence buffer crystallization, precipitation and 
consequently cause pH shifts which can accelerate drug degradation in frozen 
solutions. For example, crystallizable solutes, such as glycine, mannitol or sodium 
chloride can modify ion activity, facilitating crystallization of buffers; while non-
crystallizable excipients such as sucrose or trehalose can inhibit buffer crystallization 
(39). The citrate salts remain in an amorphous state upon freezing and drying, 
minimizing pH shifts, compared to succinates and tartrates (31, 43).  
A concept that should also be taken into account during pre-formulation studies is that 
the pH of the solution before drying has an influence on the rate of chemical reactivity 
in the resulting dried material (43). In lyophilised formulations, buffers tend to 
depress critical temperatures for the lyophilisation process; glass transition of the 




However, buffering agents are usually used in low concentrations (5-25 mM) (44). 
TRIS buffer which is included in a small number of liquid (3%; n=6) and lyophilised 
(8%; n=7) formulations has been shown to release formaldehyde in peptide 
formulations stored at 70°C. However, this does not occur at the lower temperatures 
normally employed for formulation processing or storage (43).  
Individual acids and bases can also be incorporated as pH modifiers to adjust the pH 
to a target value. Sodium hydroxide (L: 46%; n=80; LYO: 20%; n=18), hydrochloric 
acid (L: 36%; n=62; LYO: 11%; n=10) and phosphoric acid (L: 3%; n=5; LYO: 6%; 
n=5) are frequently added to liquid and lyophilised formulations, to modify their pH 
to a desired value and/or to create a salt form in combination with other buffer 
components. 
 
Key considerations: The choice of the optimal buffer system for a specific 
formulation needs to be conducted by performing compatibility studies between the 
excipient and the specific protein. However, some general rules need to be 
considered, especially for lyophilised protein products. Salts that can provoke 
significant pH shifts during freezing should be used with caution (e.g. sodium 
phosphate, sodium acetate). Despite its disadvantages, sodium phosphate is present in 
a high number of liquid and lyophilised products. Most of the commercial lyophilised 
products contain amino acids (histidine) or salts with low pH shift tendency (sodium 
citrate) as buffer systems. The absence of buffers in protein formulations can be 
considered when this does not negatively impact the quality and stability of the 
product. 
 
3.2.3 Amino acids buffers/stabilisers/bulking agents  
Amino acids play several roles in parenteral protein formulations as buffers, 
stabilisers or bulking agents. They can influence tonicity of the formulation and some 
have antioxidant properties (45-48). The solid state (amorphous or crystalline) and 
concentration of an amino acid can determine its role in a specific product. Amino 
acids use as excipients in biopharmaceutical products has increased in recent years, 
due to their multi-functionality (108 products (2007-2018, June) vs 54 products 
(1995-2007) contain amino acids). Amino acids tend to stabilise proteins by hydration 
or direct interactions (46). However, the mechanism of interaction between the 




understood. Furthermore, amino acids have a complex chemistry (acidic or basic, 
multiple functional groups) and can be included in formulation as different salt forms; 
all these factors can further impact the type of protein-amino acid interactions. Most 
of the amino acids are included in formulations in their salt form, in order to increase 
their solubility. The effect of the counter-ion, can also impact the stability of the 
protein (49).  
As shown in Figure 5. the most commonly employed amino acids in liquid and 
lyophilised commercial products are histidine (L: 16%; n=27; LYO: 34%; n=31), 
methionine (L: 12%; n=21; LYO: 6%; n=5) and glycine (L: 9%; n=15; LYO: 13%; 
n=12), followed by arginine (L: 8%; n=14; LYO: 4%; n=4). Histidine as a buffer is 
reported to provide maximal stability (50), provoking minimal pH shifts during 
freezing (51). Histidine, is a multi-functional excipient, capable in some cases of 
reducing protein aggregation and functioning as cryo/lyo-protectant during the 
lyophilisation process in addition to acting as a buffer (52, 53). Al-Hussein et al. 
revealed how the role of histidine as a stabiliser was particularly important when 
formulated in combination with sugars and when maintained in the amorphous state 
(47). The concentration at which the excipient is used in different formulations 
determine its main role, i.e. as a stabiliser/bulking agent when present in high 
concentrations or as a buffer in low concentrations. Furthermore, histidine has 
antioxidant properties, it can act as scavenger of hydroxy radicals in solution (45, 46). 
Methionine is present in a high number of liquid and lyophilised products; this 
excipient can be selected for its antioxidant properties (46, 54). Methionine is added 
to commercial products often in combination with other amino acids (e.g. histidine or 
arginine). Glycine is present in lyophilised products where it can act as a bulking 
agent, in addition to its potential buffering properties in liquid and lyophilised 
formulations (46).  
The capability of positively charged amino acids to particularly enhance the stability 
of protein formulations and suppress aggregation is reported (55). Arginine is present 
in a relatively low number of products. However, its trend of use has increased 
between 2014-2018. Amongst the 18 products containing arginine, 10 were approved 
since 2014. Arginine and its salt forms have been shown to be capable of reducing 
protein aggregation, increasing protein solubility and reducing viscosity of protein 
solutions in some cases (46, 56, 57). This effect is particularly important when 




between arginine and proteins is not completely understood. Trout et al. (58-60) 
proposed a hypothesis according to which arginine molecules self-associate in 
clusters. These amino acidic clusters create weak hydrophobic interactions (hydrogen, 
electrostatic, cation-  or Van der Waals) with guanidinium and aromatic groups of the 
protein, crowding out protein-protein interactions and avoiding aggregates formation. 
Furthermore, arginine and glutamic acid mixtures are shown to have a synergistic 
effect in increasing the solubility of proteins; this is due to the formation of additional 
hydrogen bonds with the protein in the presence of both excipients (61). 
Other amino acids such as alanine, isoleucine, leucine, lysine, phenylalanine, proline, 
threonine and valine are added to a small number of commercial products; they can 
contribute to the stability of the protein in formulation through specific interactions 
(46, 54). Arginine, histidine and lysine are reported to be amorphous in the solid state, 
while all the other amino acids are observed to be in a crystalline form after 
lyophilisation (48, 62). Concentrations of amorphous amino acids in formulations 
intended to be lyophilised should be carefully selected, since they tend to suppress 
critical temperatures (Tg’ and Tc) for lyophilisation process, increasing time and 
processing costs (49). 
 
Key considerations: Amino acids are a varied class of excipients with multi-functional 
roles and mechanisms, which are not yet completely understood especially when 
formulated in the dried state. The role of these excipients in protein formulation can 
be altered by adjusting the concentrations employed. From the analysis of this 
database, the trend of use of amino acids in protein formulations has increased in 
recent years probably due to their multi-functionality. In particular, the effect of 
combining different amino acids can provide a synergistic effect. Furthermore, some 
amino acids (basic amino acids) have properties that could be noteworthy when 
formulating proteins at high concentrations (e.g. to increase solubility, to reduce 
aggregation and viscosity) (46, 55-57, 63). 
 
3.2.4 Non-amino acids stabiliser/bulking agents 
The percentage of approved liquid and lyophilised parenteral products containing 
individual stabilisers and bulking agents are shown in Figure 6. The excipients 




stabilisers in liquid and lyophilised protein products. Additionally, some of these 
excipients can act as bulking agents, maintaining the structure of lyophilised cakes 
(e.g. mannitol) (43, 64). In this case, the solid state of the excipient within the 
formulation determines its role. For example, mannitol which tends to crystallise is 
used as a bulking agent, while sucrose, which maintains its amorphous state, acts 
mainly as a stabiliser in lyophilised products. Due to the lack of this solid-state 
information in the EPAR data, it was difficult to determine the specific role of these 
excipients in commercial products. For this reason, stabilisers have been combined 
with bulking agents in a single category. The list of excipients that have been 
referenced as bulking agents (excluding amino acids) is broad, consisting of human 
albumin, maltose, mannitol, sorbitol, sucrose and trehalose (38, 43, 45, 65-67). 
However, sucrose and trehalose are predominately incorporated in lyophilised 
products as stabilisers in an amorphous state, rather than bulking agents in their 
crystalline state.  
Three different hypotheses have been proposed to explain the mechanism by which 
excipients are able to physically stabilise proteins (vitrification, exclusion and water 
replacement theories) (68-70). For many formulations the stabilisation may be due to 
the cumulative effect of these three different mechanisms. Excipients contribute to 
protein stabilisation by a range of mechanisms including direct interactions, 
minimising protein-protein interaction and aggregation, and stabilising the folded 
state of the protein (71-73).  
Bulking agents are employed in lyophilised formulations of low dose (high potency) 
drugs that do not have the necessary bulk to support their own structure (total solid 
content < 2% (w/v)) (43, 64). While protein integrity and stability are not necessarily 
related to the cake structural defects, requirements for an intact cake appearance tend 
to be observed for commercial lyophilised products (74, 75). A review by Patel et al. 
(75) establishes some guidelines of what is acceptable from a product quality and 
regulatory perspective in terms of visual cake appearance. The presence of a 
crystalline compound in formulation can also reduce the reconstitution time of 
lyophilised products containing high concentrations of protein (76). 
The most common stabilisers included in liquid formulations are glycerol (17%; 
n=29), sucrose (16%; n=28), and mannitol (14%; n=24). Due to the increased 
requirement for physical stabilisation of the protein during the lyophilisation process, 




lyophilised formulations. Non-amino acids stabilisers/bulking agents most frequently 
present in lyophilised products are sucrose (59%; n=53), mannitol (33%, n=30) and in 
a lower number of products trehalose (10%; n=9) and human albumin (7%; n=6). 
Glycerol is exclusively included in liquid products where it can have multiple roles; 
this excipient is a co-solvent/solubilising agent, which can serve as a tonicifier as 
well. Absence of glycerol in lyophilised commercial products may be attributed to its 
plasticising effect on the product’s glass transition and to the stability issues observed 
in some formulations, where the increase in protein mobility provokes deamidation 
(68). Sucrose can act as a cryo/lyo-protectant in lyophilised formulations; it is 
maintained in an amorphous state after lyophilisation with moisture contents lower 
than 2.5% (68). On the contrary, mannitol is widely present in lyophilised products as 
a bulking agent due to its capability to crystallize and support the lyophilised cake.  
Sugars and polyols are frequently used as stabilisers (cryo/lyo protectants) and 
bulking agents in lyophilised products. However, carbohydrates with low Tg’ values, 
such as sorbitol (Tg’= -45 °C) (77) can increase lyophilisation process time. This 
explains the absence of sorbitol as an excipient in lyophilised commercial 
formulations. Furthermore, sorbitol can crystallize over time and this needs to be 
considered in formulating a product intended to be lyophilised (77).  
Despite several reported advantages, trehalose use is not widespread amongst 
commercial products compared to other sugars (L: 6%; n=10 ; LYO: 10%; n=9). 
However, eight new products containing trehalose were approved between 2017-
2018. Trehalose has good aqueous solubility, low hygroscopicity, high hydration 
number (due to its hydrophilicity), good hydrolytic stability in extreme pH and upon 
beta-glycosidase action. This sugar has a higher Tg compared to other carbohydrates; 
Tg value in presence of 0.3% residual water content was reported to be approximately 
111°C for trehalose, while it is approximately 65°C for sucrose (43, 69, 70). 
However, the following reasons may limit trehalose use as an excipient. Firstly, 
business reasons can determine a company’s choice of excipient; trehalose is more 
expensive than other stabilising sugars, such as the more commonly employed 
sucrose (78). Where comparative stability can be achieved with sucrose, logistic and 
business rationale would influence excipient choice. Secondly, the use of trehalose as 
stabiliser in some cases was observed to be less effective in comparison to sucrose. 
Jovanović et al. (79) reported significant changes in the tertiary structure of lysozyme 




in formulation as an heterogenous system formed by different crystalline phases. This 
polymorphism renders its behaviour in formulation difficult to predict, with a 
potential impact on stability (79-81). The transformation paths that trehalose can 
undergo depend on several factors, including the solid-state (amorphous or 
crystalline) and the dosage form (liquid or solid) as well as the dehydration process 
and residual moisture levels in the product (80, 82). The use of trehalose could be 
preferred over other carbohydrates if there is a significant improvement in terms of 
product stability or process efficiency. 
Reducing sugars (e.g. lactose and maltose) should be avoided due to potential 
interactions with amino acid side chains, which can cause chemical alteration of the 
proteins (Maillard reaction or glycation) (68). Indeed, maltose is present in only one 
lyophilised commercial product (ORENCIA
®
 (abatacept)) at a concentration of 50 
mg/ml and at a ratio of 2:1 maltose to abatacept in the lyophilised form prior to 
reconstitution (16). Maltose is reported on the EPAR’s scientific discussion to be used 
as a stabiliser/bulking agent at the concentration in formulation (83). This sugar is 
included in the ORENCIA
®
 (abatacept) lyophilised product intended to be 
administered intravenously but replaced by sucrose in the corresponding 
subcutaneous liquid product. It is important to note that the Maillard reaction is 
favoured in alkaline or acidic conditions, and that the pH of this product after 
reconstitution is maintained neutral (pH 7.2-7.8). Trace level reducing sugars can also 
be found in non-reducing excipients such as mannitol, maltitol and sucrose. Hence, 
care should be taken regarding the quality of the excipients selected (68, 84). 
Recrystallisation of sugars and polyols during manufacture and storage should be 
avoided, because conversion between amorphous and crystalline states can 
compromise the protein stability. Mannitol at high concentrations can provoke vial 
breakage due to recrystallisation during the lyophilisation process (primary drying 
phase) and storage (68). For these reasons, the introduction of an annealing step in the 
lyophilisation cycle is required when crystalline components are present in protein 
formulations. In some formulations, different sugars/polyols are used in combination, 
so one excipient behaves as a stabiliser and the other as a bulking agent, for example 
ENBREL
® 
(etanercept) contains sucrose and mannitol. The former is capable of 
stabilising the protein, whereas the latter prevents the collapse of the cake. Pikal et al. 
(85) reported similar examples of formulations containing glycine as a stabiliser and 




amorphous and crystalline compounds is the possibility to reduce the lyophilisation 
cycle time, conducting the primary drying above the Tg’ value of the amorphous 
phase (86). The recommended molar ratio of protein to stabiliser is 360:1 (weight 
ratio 1:1), whereas it is usually higher for bulking agents (44, 51, 64, 87). 
Human albumin can have a number of functions in parenteral formulations, as a 
stabiliser (38, 45), bulking agent and tonicifier (38), but it is not employed in recent 
products possibly due to its potential risk of introducing contaminants (e.g. viruses) 
(38). Dextran 40 is included in one lyophilised antibody-drug conjugate product 
MYLOTARG® (gentuzumab ozogamicin), approved in 2018. Dextran at 
concentrations of 9.1 mg/ml is reported to act as a bulking agent (EPAR’s scientific 
discussion) (88). 
Key considerations: The physical state of the excipient and the dosage form (liquid or 
lyophilised) need to be evaluated in the selection of a stabiliser/bulking agent. 
Sorbitol and glycerol can be used in liquid formulations, but they are not 
recommended in lyophilised products. Reducing sugars should be avoided in both 
liquid and lyophilised products because of the possibility to undergo Maillard 
reaction, altering the chemistry and the activity of the protein. Mannitol and sucrose 
are widely used especially in lyophilised commercial products. Mannitol as a bulking 
agent is in a crystalline form, hence the introduction of an annealing step in the 
lyophilisation process is required. Trehalose is a promising excipient, but its 
employment is limited partially due to its relative high costs. 
 
3.2.5 Surfactants 
Surfactants in both liquid and lyophilised formulations stabilise the protein, increasing 
its solubility and minimising interface interactions (89). Surfactants stabilise proteins 
by the following mechanisms; a) direct interactions of the surfactant molecules with 
hydrophobic domains exposed on the protein surface and b) interfacial competition, 
i.e. surfactant occupancy of the surface is more thermodynamically favoured 
compared to the protein occupancy (89). The use of surfactants in lyophilised 
products reduces the surface tension at the ice-water interface, promotes protein 
refolding and prevents aggregation (25, 70). High concentration protein formulations 
require surfactants in order to improve solubility of the protein and overcome 




protect highly concentrated proteins from mechanical agitation and manipulation (e.g. 
during syringeability) and reduce the reconstitution time of lyophilised products (9, 
90).  
A relatively small number of surfactants are included in the liquid and lyophilised 
products. The main excipients are polysorbate 80 (L: 32%, n=55; LYO: 41%, n=37), 
polysorbate 20 (L: 26%, n=45; LYO: 18%, n=16) and poloxamer 188 (L: 7%, n=12; 
LYO: 3%, n=3). Several of both formulation types (L: 35%; n=61; LYO: 38%; n=34) 
do not contain any surfactants, most of which are insulin-based products. The reason 
for the absence of surfactants in these commercial products was investigated. 
However, no clear trend was observed when evaluating products by year of approval, 
class of therapeutic protein or dosage form. The majority of surfactants included in 
protein formulations are non-ionic. Non-ionic surfactants are preferred over ionic 
surfactants which can denature proteins (89); but they are also selected for their low 
toxicity and reduced sensitivity to the presence of electrolytes (91). Non-ionic 
surfactants are normally employed in a concentration range between 0.0003-0.3% 
(w/v) (70). Polysorbates are composed of fatty acid esters of polyoxyethylene sorbitan 
monolaurate (polysorbate 20) and polyoxyethylene sorbitan monooleate (polysorbate 
80). The main disadvantage of polysorbates is their ability to undergo hydrolysis and 
autoxidation of the side-chains, resulting in hydrogen peroxide formation and 
development of short chain acids (formic acid). These sub-products can compromise 
the stability of a biopharmaceutical formulation (e.g. increasing the oxidation rate of 
proteins) and the safety of the product if accumulated in high amounts (89, 91, 92).  
The concentration of polysorbates in a pre-formulation stage is selected considering: 
a) critical micelle concentration (CMC) and b) the possibility of degradation through 
the manufacturing process or during storage of the product. The concentration of 
surfactant needs to be carefully determined at the pre-formulation stage because of 
these disadvantages. An alternative surfactant is poloxamer 188, a triblock copolymer, 
included in a small number of liquid and lyophilised protein products (89). In 
comparison to polysorbates, poloxamer 188 inhibits protein adsorption through a 
different mechanism; which is independent from the interface affinity and allows 
formation of protein-surfactant complexes (93). The mechanism by which surfactants 
reduce protein adsorption can also impact the concentration used in formulation, 






 solution for infusion (400 IU/ml) or injection (100 IU/ml) in 
the new formulation (EPAR updated 04/06/2018). 
 
Key considerations: The most commonly employed surfactants are polysorbates. 
However, the impact of the formation of degradation sub-products on protein stability 
should be evaluated at the pre-formulation stage. If their employment is required, the 
minimum functional concentration should be included and the impact of their 
variability on product and process stability be assessed. Poloxamers represent an 
alternative to the polysorbates. 
 
3.2.6 Preservatives 
Parenteral liquid products in multi-dose vials require the presence of a preservative to 
minimise microbial contamination. One of the main drawbacks of antimicrobial 
preservatives is their significant volatility and reactivity. Furthermore, many examples 
of interactions between various preservatives and drugs, excipients, packaging and 
filter materials are reported in literature (32, 68, 94). Preservatives are usually used in 
low amounts (0.002-1% (w/v)) (32), however, concentrations above 1% (w/v) have 
been noted in commercial products. Metacresol, phenol, benzyl alcohol and 
benzalkonium chloride were identified as the main preservatives included in protein 
products. Preservatives are mainly incorporated in multi-dose products (L: n=48; 
LYO: n=5) and in multi-dose lyophilised products they are always added to the 
solvent for reconstitution. Metacresol (L: 19%, n=33; LYO: 1%, n=1) and phenol (L: 
14%, n=24; LYO: 0%) are the most frequently used preservatives, they are included 
respectively in 69% and 50% of the liquid multi-dose products. Metacresol is more 
active against gram +ve than gram -ve bacteria (45).  
Phenol is the most common preservative in liquid insulin-based formulations and is 
active against a broader spectrum of microorganisms including viruses and 
mycobacteria. Phenol activity increases in acidic and concentrated solutions as well as 
at higher temperature. It has been reported that monoclonal antibody formulations 
containing phenol can lead to soluble and insoluble aggregates formation (4, 38, 45). 
Benzyl alcohol is present in four liquid multiple use products (8% of the multi-dose 
liquid products) However, it is also added to two liquid single use products 
(PEGASYS
®
 (peginterferon alfa-2a) and REBIF
®




as stabiliser to prevent oxidation (EPAR’s scientific discussion) (95). Benzyl alcohol 
is also added to four lyophilised formulations (80% of the multi-dose lyophilised 
products). Benzalkonium chloride (L: 1%, n=1; LYO: 1%, n=1) is a quaternary 
ammonium compound active against gram +ve and gram -ve bacteria. Both the 
products containing benzalkonium chloride are intended for multiple use. 
 
Key considerations: Metacresol and phenol are the most common preservatives 
employed in liquid commercial products. The use of preservatives is particularly 
required in multi-dose preparations. Metacresol, benzyl alcohol and benzalkonium 
chloride were observed to be added to the diluent for reconstitution of a low number 





Tonicifiers are added to protein formulations to create isotonic solutions for parenteral 
administration. The delivery of a non-isotonic solution through a parenteral route of 
administration can cause damage to the tissue and pain at the site of administration. 
Osmolality values between 280-300 mOsm/Kg and <600 mOsm/Kg for intravenous 
and subcutaneous administration respectively represent the osmolality limitations in 
developing parenteral protein formulations (35). The usual range of osmolality 
observed in commercial protein products is between 210-440 mOsm/Kg (22). The 
achievement of iso-osmolar biopharmaceutical products is particularly challenging for 
high concentration protein formulations due to the high amount of protein and the 
overall high solute concentration. Sodium chloride (NaCl) and potassium chloride 
(KCl) are the two main tonicifiers, however all formulation components can 
contribute to the product tonicity. NaCl is used in a relatively high percentage of 
liquid (36%; n=62) and lyophilised (42%; n=38) commercial products and is added to 
formulations, especially in the liquid form, also as a stabiliser. Sodium chloride was 
reported to reduce the viscosity of a reconstituted high concentration protein 
formulation (90) and to have a stabilising effect on insulin based formulations (96). 
This excipient was also observed to inhibit mannitol crystallization in frozen solutions 
(97). However, the use of NaCl is not optimal for lyophilised formulations, due to the 




protein mobility (38, 81). This could be the justification for six lyophilised products, 
including BETAFERON
®
 (interferon beta-1b) and ALPROLIX
® 
(eftrenonacog alfa), 
wherein sodium chloride is added to the diluent provided for reconstitution rather than 
to the lyophilised product (98). KCl is exclusively present in a low number of liquid 
formulations (L: 1%, n=2). The inclusion of sugars, polyols, amino acids and salts all 
increase the tonicity of a protein formulation. Hence, excipients reported in sections 
3.2.3 and 3.2.4 contribute to the tonicity of the product. Furthermore, the impact of 
these excipients on the ionic strength of the formulation should be evaluated, since a 
high ionic strength can compromise the protein stability, promoting protein 
aggregation (99). 
 
Key considerations: Achieving iso-osmolarity is recommended for products intended 
to be administered through parenteral routes. Tonicity of a product can be adjusted 
using NaCl or KCl, but also by using specific concentrations of sugars, polyols and 
amino acids in formulation. NaCl is present in a high number of lyophilised products, 
however care should be taken during lyophilisation process design due to its 
suppression effect on the eutectic temperature of the formulation. 
 
3.2.8 Other excipients 
The ‘other excipients’ category contains mainly complexing agents, antioxidants and 
solubilising agents. All these excipients have stabilising properties, but are not 
included in the main category stabilisers/bulking agents for two reasons: 1) they are 
not bulking agents (usually used in low concentrations); 2) they are present in a low 
number of products and/or they are stabilising agents via specific mechanisms. The 
percentages of approved liquid and lyophilised parenteral products containing ‘other 
excipients’ are listed along with their main functions in Table II. (38, 45, 96, 100-
106). 
Edetic acid or edetate salt (EDTA) is used as a complexing agent in liquid 
formulations (L:3%, n=6;). EDTA can form complexes (chelates) with metal ions 
which are removed from the solution in a process defined as sequestering. Heavy 
metals have the capability to catalyse autoxidation, so their removal can be required 
for stabilisation. Usually employed EDTA concentrations are between 0.005-0.1% 
(w/v) (45). EDTA also possess antioxidant and antimicrobial properties and it can be 




(45). Calcium chloride (L: 3%; n=5; LYO: 19%; n=17) is usually employed as a 
complexing agent in lyophilised products containing coagulation factors. Coagulation 
factors is a class of therapeutic proteins whose activity and stability is promoted in 
presence of calcium ions (38). 
Antioxidants minimise oxidative reactions of the API or excipients over the shelf-life 
of the product. Glutathione is an antioxidant found exclusively in two lyophilised 
products, ADVATE
®
 (octocog alfa) and ADYNOVI
®
 (rurioctocog alfa pegol), both 
based on coagulation factors. Glutathione behaves as a reducing agent creating 
disulphide bonds with cysteine residues of proteins, preventing their oxidation. This 
process is aided by the thiol groups of glutathione which are oxidised forming 
glutathione disulphide (GSSG) (107-109). 
Nicotinamide is included in one recent liquid product, FIASP
®
 (insulin aspart). This 
excipient is reported to reduce the self-association of insulin, promoting the rapid 
absorption of the monomeric form, which results in a faster action. Protamine 
sulphate (L: 5%, n=9) is a specific excipient employed exclusively in liquid insulin 
products to prolong the action of the therapeutic protein. Zinc acetate (L: 3% n=5), 
zinc chloride (L: 10% n=17) and zinc oxide (L: 3% n=5) are also additives used 
specifically in liquid formulations based on insulin. The presence of zinc ions in the 
formulation at specific concentrations promote the association of insulin molecules in 
hexamers, increasing the protein stability and prolonging its activity (96).  
Finally, recombinant human hyaluronidase (rHuPH20) is a novel excipient that 
enhances protein bioavailability following subcutaneous administration. It modifies 
and creates conduits in the interstitial matrix to promote dispersion of molecules 
including proteins (105). This excipient, exclusively employed in three liquid 
antibody products intended to be administered subcutaneously, is reported to reduce 
administration times in comparison to the corresponding intravenous products (110).  
 
Key considerations: The employment of ‘other excipients’ can be due to the necessity 
to further improve the performance of the product, overcoming specific issues. Their 
inclusion in formulation should be evaluated case by case.  
 
3.2.9 Additional considerations in excipient selection 
Data analysis showed how qualitative and/or quantitative composition can vary for 




lyophilised); 2) route of administration; 3) API concentration; 4) primary packaging 
container; 5) different formats of liquid formulations (concentrate vs solution). 







 (etanercept) and XOLAIR
®
, 
(omalizumab) are all examples in which the excipient composition differs between the 
liquid and lyophilised product. In particular, a replacement of other stabilisers (amino 










 (etanercept), instead, the sodium phosphate salt included 
in the liquid form is replaced by the TRIS salt in the lyophilised form. Mannitol is 
also added, in combination with sucrose, to the lyophilised product. HERCEPTIN
®
 
(trastuzumab) contains methionine and rHuPH20, which are not present in the 
lyophilised product. The route of administration of a specific product can also impact 
the choice of the excipients; MABTHERA
®
 (rituximab) is an antibody product whose 
subcutaneous formulation contains rHuPH20. This excipient is excluded from the 
product for intravenous use for reasons related to its function and discussed in section 
3.2.8. The different API concentrations can require varied qualitative and quantitative 
excipient compositions to reach an adequate formulation stability, this is the case of 
HUMIRA
®
 (adalimumab) and OMNITROPE
®
 (somatropin). Furthermore, 
LANTUS
®
 (insulin glargine) and TOUJEO
®
 (insulin glargine) liquid products do not 
contain polysorbate 20 in the cartridges; however, the surfactant is present in the 
vials. Some excipients can be added to specific types of liquid formulations, for 
instance, STELARA
®
 (ustekinumab) concentrate for solution for IV infusion (20 
mg/ml) contains EDTA, which is not included in the highly concentrated (80 mg/ml) 
subcutaneous liquid solution. Therefore, excipients should be carefully selected 
considering several factors with the aim of improving the stability of a target/final 
product with specific characteristics.  
Regarding lyophilised products, the addition of specific excipients to the diluent for 
reconstitution could improve stability of the product during its life span between 
manufacture and administration. As discussed before, sodium chloride or 
preservatives can be included directly in the diluent for reconstitution. Furthermore, 
REFIXIA
®
 (nonacog beta pegol) contains 4.2 ml of 10 mM histidine solution in a 
prefilled syringe as diluent for reconstitution which was observed to improve the 
stability of the final product (111). BLINCYTO
®




solution (containing lysine, citric acid, polysorbate 80 and sodium hydroxide) to 
prevent adsorption of blinatumomab to the surfaces of administration; hence, it is 
added to the IV infusion bag (112). 
 
3.3 Approved antibody products  
3.3.1 Antibody concentration and relationship with the route of administration 
The number of antibody products approved up to June 2018 was 94 (L: 73%, n=69; 
LYO: 27%, n=25). Figure 7 shows the trend in the number of liquid and lyophilised 
parenteral antibody products approved per year from 1998, when the first antibody 
product was approved, to June 2018. Liquid formulations are more common than 
lyophilised formulations (11) and the number of marketed products per year has 
significantly increased in 2017. The most common class of antibodies in approved 
products is IgG1 (L: 70% n=48; LYO: 84% n=21). A lower number of liquid products 
contain IgG4 (L: 10% n=7), human normal IgG (L: 9% n=6), and IgG2 (L: 7% n=5) 





 (certolizumab pegol)) and one liquid product contains an IgG2/4 
(SOLIRIS
®
 (eculizumab)). Lyophilised products are predominately based on IgG1 
with three products containing IgG4. Only two bispecific antibody products are 
currently approved by the EMA. One HEMLIBRA
®
 (emicizumab) is formulated as a 
liquid and the second BLINCYTO
®
 (blinatumomab) as a lyophilised product. The 
four approved antibody-drug conjugates (ADC) are all in a lyophilised dosage form. 
No particular trend was observed in the use of specific excipients for the different 
classes of antibody. However, human normal immunoglobulin products tend to have a 
low number of excipients in formulation (1 or 2).   
Figure 8 shows the antibody concentration (mg/ml) in liquid products before dilution 
and in lyophilised products following reconstitution. Approximately half of these 
products (L: 48%; LYO: 68%) contain antibodies at a concentration ≤ 50 mg/ml. 
Figure 9 reports the amount of therapeutic protein per vial (mg/vial) for lyophilised 
products. Information regarding the fill volume of the vials before lyophilisation was 
not provided in the EPAR data, therefore it is not possible to determine the initial 
concentration of protein or the total solute concentration prior to lyophilisation. 
However, a higher percentage of products contain protein in amounts ≥100 mg/vial. 
Analysis of products’ protein concentration (lyophilised products after reconstitution) 




half of the commercial antibody products are intended to be administered 
intravenously (60%). Antibody formulations with high concentrations of protein 
(>50-mg/ml) are more commonly administered subcutaneously. The antibody 
concentrations in formulation depends on the therapeutic effect and the route of 
administration selected to deliver the dose. For example, LUCENTIS
®
 (ranibizumab), 
a product for the treatment of macular degeneration and edema, myopia and diabetes 
complications, is formulated at a relatively low concentration (10 mg/ml) and is 
intended to be administered by intravitreal route (113). 
 
3.3.2 Qualitative and quantitative excipient composition  
The categories of excipients included in liquid and lyophilised antibody products are 
shown in Figure 11. Antibody formulations contain non-amino acids buffers in 
approximately half of both liquid (54%; n=37) and lyophilised (56%; n=14) 
commercial products. Amino acids are also added to approximately 50% of the 
products in both dosage forms (L: 54%; n=37; LYO: 52%; n=13). A high number of 
liquid formulations contain non-amino acids stabilisers (L: 59%, n=41), whereas all 
lyophilised products contain non-amino acids stabilisers/bulking agents (LYO: 100%, 
n=25). Most of the liquid and lyophilised products include surfactants (L: 87%, n=60; 
LYO: 88%, n=22). Preservatives are not present in any antibody formulations, which 
are always provided in a single use dosage form. Sodium chloride and potassium 
chloride are more frequently added to liquid products (L:36%, n=25) where they can 
act as tonicifiers and/or stabilisers. Excipients classified as ‘other excipients’ are only 
included in a small number of liquid products (13%; n=9). 
Figure 12 shows the percentage of liquid and lyophilised antibody formulations that 
contain individual excipients. Amongst non-amino acids buffers the most commonly 
employed excipients are: sodium citrate (L: 20%, n=14; LYO: 20%, n=5) and sodium 
phosphate (L: 12%, n=8; LYO: 28%, n=7). As for protein products, sodium acetate 
(L: 22%, n=15) is observed to be included exclusively in liquid products. Histidine 
(L: 39%; n=27; LYO: 40%; n=10) is the most common amino acid added to liquid 
and lyophilised antibody products, followed by the amino acid glycine (L:12%; n=8; 
LYO: 8%; n=2). Arginine is more frequently used in the liquid forms (10%; n=7) than 
the lyophilised forms (4%; n=1). Methionine is included exclusively in liquid 




Sucrose is the most common non-amino acid stabiliser and is present in most of the 
lyophilised products (L: 20%, n=14; LYO: 72%, n=18). Sorbitol is included 
exclusively in liquid products (10%; n=7). Surfactants employed comprise 
polysorbate 80 (L: 55%, n=38; LYO: 64%, n=16), polysorbate 20 (L: 29%, n=20; 
LYO: 24%, n=6) and to a lesser extent poloxamer 188 (L: 3%, n=2; LYO: 0%). 
Sodium chloride is present in a high number of liquid products (L: 36%, n=25) and 
only three lyophilised products with low concentrations of antibodies, two of which 
are antibody-drug conjugates (ADC). Finally, excipients classified as ‘other 
excipients’ and employed in antibody formulations include chelating agents (EDTA 
and pentetic acid), calcium chloride as complexing agent and rHuPH20. rHuPH20 is 




 (trastuzumab) and 
HYQVIA
®
 (human normal immunoglobulin), all liquid products based on antibodies. 
The quantitative composition of 88 out of 94 liquid and lyophilised antibody 
commercial products was investigated consulting accredited sources and summarised 
in Table III. (8-10, 114). Some of the products for which the quantitative 
composition was not available are biosimilars to other reference products. Biosimilars 
in some cases can have the same qualitative and/or quantitative excipient 
composition. For example, MVASI® (bevacizumab) is a biosimilar, having the same 
formulation of the reference product AVASTIN
®
 (bevacizumab) (115). On 
MVASI
®
’s scientific discussion (EMA) it is reported: ‘The finished product was 
developed to have the same formulation, route of administration, dosage form and 
strength as the reference product Avastin’ (116). Furthermore, some biosimilars 







) and have been approved by the EMA following a 
multiple marketing authorisation application (117).  
The pH values at which listed antibody formulations were buffered are in a range 
between pH 4.6 and 8.2. The trend observed in the use of excipients for antibody 
formulations matches with the results obtained for protein formulations, probably 
because antibodies form the main class of therapeutic proteins. Hence, additional 
information is reported below only for other excipients added to antibody products 
and not discussed in previous sections. For example, proline (24-28.78 mg/ml) is 
reported in the EPAR’s scientific discussion of some liquid antibody products to be a 
viscosity and tonicity modifier or a stabiliser (118, 119). EDTA and pentetic acid are 




between 0.02-1 mg/ml and 0.01-0.04 mg/ml, respectively. Calcium chloride is 
reported to be at concentrations of 0.4 mg/ml in the antibody product HYQVIA
®
 
(human normal Ig). Finally, rHUPH20 is added at concentrations of 2000 units/ml in 
MABTHERA
®
 (rituximab) and HERCEPTIN
® 
(trastuzumab). However, in 
HYQVIA
®
 (human normal Ig) rHUPH20 (160 units/ml) is provided in a separate vial 
containing other excipients, and added to the antibody product prior to administration. 
 
4. Conclusions 
The information summarised in this overview aims to update formulation scientists on 
the trends of excipients’ use in approved protein products, aiding them in the selection 
of excipients for the development of new formulations. The data presented details the 
most common excipients included in liquid and lyophilised formulations classified 
into functional categories, focusing in particular on antibody products. The discussion 
also provides information and key considerations in the use of specific excipients, 
analysing their role and rationale of use in protein formulations with different dosage 
form (liquid or lyophilised). A shortcoming of the EPARs data is the limited 
quantitative compositional information on approved products. However, this 
information was collected for most of the protein formulations using other publicly 
available sources (FDA and Marketing Authorisation Holder). Of note from this 
overview is the low number of ‘novel’ excipients introduced within the products 
approved over the period analysed. This may be due to many factors; such as the 
employment of an usual ‘platform approach’ formulation strategy (9), the regulatory 
requirements of approving new excipients for parenteral formulations (71), as well as 
companies’ marketing/commercial reasons that can drive the choice of one excipient 
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Figure 1. Trend of liquid and lyophilised parenteral protein products approved per year by the EMA 
between 1995-2018 (June) (*Last updated: 18/06/2018). 
Figure 2. Classes of therapeutic proteins included in liquid and lyophilised parenteral products. 2a) Pie 
chart of the total number of products; 2b) Pie chart of the split between liquid and lyophilised products. 
*‘Other’ class includes types of therapeutic proteins present in a percentage of commercial products <3% 
(analgesic peptide, antiangiogenic agent, anticoagulant, antiplatelet, antithrombin/thrombolytic, growth factor, 
HIV infusion inhibitor, muramyl peptide derivative, toxin, calcimimetic peptide) 
Figure 3. The percentage of liquid and lyophilised parenteral protein products that contain excipients from 
each of the excipient categories: Non-amino acids BUFF (buffers); Amino acids BUFF/S/BA 
(buffers/stabilisers/bulking agents); Non-amino acids S/BA (stabilisers/bulking agents); Surfactants; 
Preservatives; Tonicifiers and Other excipients. 
Note: The function of these excipients as bulking agents is only relevant for lyophilised products 
 
*‘Other excipients’ category consists of complexing agents, antioxidants, solubilising agents and excipients 
specific to individual formulations 
Figure 4. The percentage of approved liquid and lyophilised parenteral protein products containing 
individual non-amino acids buffers. 
Figure 5. The percentage of approved liquid and lyophilised parenteral protein products containing 
individual amino acids buffers/stabilisers/bulking agents. 
Note: The function of these excipients as bulking agents is only relevant for lyophilised products 
 
Figure 6. The percentage of approved liquid and lyophilised parenteral protein products containing 
individual non-amino acids stabilisers/bulking agents. 





Figure 7. Trend of liquid and lyophilised parenteral antibody products approved per year by the EMA 
between 1995-2018 (June) (*Last updated: 18/06/2018). 
Figure 8. Range of therapeutic concentrations (mg/ml) of liquid and lyophilised parenteral antibody 
products. 
*for lyophilised formulations intended after reconstitution 
Figure 9. Amount of antibody per vial (mg/vial) for lyophilised parenteral antibody products. 
Figure 10. Relationship between ranges of antibody concentrations (mg/ml) and route of administration. 
*for lyophilised formulations intended after reconstitution 
Figure 11. The percentage of liquid and lyophilised parenteral antibody products that contain excipients 
from each of the excipient categories: Non-amino acids BUFF (buffers); Amino acids BUFF/S/BA 
(buffers/stabilisers/bulking agents); Non-amino acids S/BA (stabilisers/bulking agents); Surfactants; 
Preservatives; Tonicifiers and Other excipients.  
Note: The function of these excipients as bulking agents is only relevant for lyophilised products 
 
*‘Other excipients’ category consists of complexing agents, antioxidants, solubilising agents and excipients 
specific to individual formulations 
Figure 12. The percentage of liquid and lyophilised parenteral antibody products that contain individual 
excipients from each of the excipient categories: Non-amino acids BUFF (buffers); Amino acids BUFF/S/BA 
(buffers/stabilisers/bulking agents); Non-amino acids S/BA (stabilisers/bulking agents); (SURF) 
Surfactants; (T) Tonicifiers; (OE*) Other excipients. 
 
Note: The function of these excipients as bulking agents is only relevant for lyophilised products 
 
* (OE) ‘Other excipients’ category consists of complexing agents, antioxidants, solubilising agents and excipients 
specific to individual formulations 
Supplementary information captions: 
Table 1. Database of approved liquid parenteral protein products listed alphabetically (Last updated 
18/06/2018) 







Table I. More common individual excipients classified into functional categories and listed by 
descending frequency of use in liquid and lyophilised parenteral protein products (percentage 
and number of formulations containing each excipient and range of excipient concentrations 
included in approved products) 
  
Excipient class Liquid Lyophilised 
Non-amino acids 
Buffering agents 
Sodium phosphate (33%; 
n=58) 
(0.2-14.8 mg/ml) 
Sodium phosphate (32%; 
n=29) 
(0.2-14.4 mg/ml) 
Sodium acetate (19%; 
n=33) 
(0.4-6.8 mg/ml) 
Sodium citrate (20%; n=18) 
(1.1-34.8 mg/ml) 
Sodium citrate (17%; 
n=29) 
(0.5-14.7 mg/ml) 





Histidine (16%, n=27) 
(0.9-4.3 mg/ml) 
Histidine (34%; n=31) 
(0.7-8.9 mg/ml) 
Methionine (12%; n=21) 
(0.1-3 mg/ml) 
Glycine (13%; n=12) 
(0.2-25 mg/ml) 
Glycine (9%; n=15) 
(0.1-18.8 mg/ml) 
Methionine (6%; n=5) 
(0.06-0.5 mg/ml) 
Arginine (8%; n=14) 
(4.4-42.1 mg/ml) 




Glycerol (17%; n=29) 
(16-20 mg/ml) 
Sucrose (59%; n=53) 
(1.9-160 mg/ml) 
Sucrose (16%; n=28) 
(10-200 mg/ml) 
Mannitol (33%; n=30) 
(10.6-80 mg/ml) 
Mannitol (14%; n=24) 
(1.9-54.6 mg/ml) 





Sorbitol (10%; n=17) 
(20-50 mg/ml) 
Human albumin (7%; n=6) 
(8-15 mg/ml) 
Surfactants Polysorbate 80 (32%; 
n=55) 
(0.01-2 mg/ml) 
Polysorbate 80 (41%; n=37) 
(0.05-0.7 mg/ml) 
 Polysorbate 20 (26%; 
n=45) 
(0.01-2 mg/ml) 
Polysorbate 20 (18%; n=16) 
(0.04-0.4 mg/ml) 
 Poloxamer 188 (7%; n=12) 
(0.1-8 mg/ml) 
Poloxamer 188 (3%; n=3) 
(1-1.2 mg/ml) 
Preservatives* Metacresol (19%; n=33) 
(1.5-3.2 mg/ml) 
Benzyl alcohol (4%; n=4) 
(9-14.9 mg/ml) 
 Phenol (14%; n=24) 
(0.8-5.7 mg/ml) 
Benzalkonium chloride (1%; 
n=1) 
(NA) 
 Benzyl alcohol (3%; n=6) 
(9-10 mg/ml) 
Metacresol (1%; n=1) 
(3.2 mg/ml) 
Tonicifiers Sodium chloride (36%; 
n=62) 
(0.6-11.7 mg/ml) 
Sodium chloride (42%; 
n=38) 
(0.3-27 mg/ml) 





*Preservatives in lyophilised products are added to the diluent for reconstitution 
Note: the function of these excipients as bulking agents is only relevant for lyophilised products 
 
Table II. Examples of other excipients with specific functions included in liquid and lyophilised 
parenteral protein products  
 Function Liquid Lyophilise
d 
Reference 
Calcium chloride Complexing agent; 
preservative 






EDTA  Complexing agent (chelating 
agent) 
3%; n=6 0%; n=0 (45) 
Glutathione Antioxidant 0%; n=0 2%; n=2 (100) 
Nicotinamide Antioxidant; solubilizing 
agent 
1%; n=1 0%; n=0 (45) 
Pentetic acid Complexing agent (chelating 
agent) 
2%; n=3 0%; n=0 (45) 
Protamine sulphate* Complexing agent to 
prolong insulin activity 




following SC administration 
2%; n=3 0%; n=0 (104, 105) 
Urea Stabiliser (dissolving 
aggregates)  
1%; n=1 1%; n=1 (103) 
Zinc acetate* 
Zinc chloride* 
Zinc oxide * 
Complexing agent to 














Liposomal targeting 0%; n=0 1%; n=1 (106) 




Table III. Quantitative composition of individual excipients included in 88 approved liquid and 
lyophilised parenteral antibody products, listed by ascending values of concentration 
(16,17,22,28) (Last updated 18/06/2018)   
 
Excipient name Excipient quantitative composition of approved LIQUID antibody products Excipient quantitative composition of approved LYOPHILISED 
antibody products 
Potassium phosphate  
(Non-amino acids BUFF)1 
LEMTRADA® (alemtuzumab) 0.2 mg/ml  SIMULECT® (basiliximab) 1.44 mg/ml 
Sodium acetate 
(Non-amino acids BUFF) 1 
 
AMGEVITA® (adalimumab) 0.6 mg/ml acetic acid; BAVENCIO® (avelumab) 0.6 
mg/ml; SOLYMBIC® (adalimumab) 0.6 mg/ml acetic acid; TECENTRIQ® 
(atezolizumab) 0.83 mg/ml acetic acid; DUPIXENT® (dupilumab) 1 mg/ml; 
REPATHA® (evolocumab) 1.2 mg/ml; CIMZIA® (certolizumab pegol) 1.36 mg/ml 
PROLIA® (denosumab) 17 mM (1.4 mg/ml); XGEVA® (denosumab) 18 mM (1.5 
mg/ml); OCREVUS® (ocrelizumab) 20 mM (EMA); 2.14 mg/ml, 0.25 acetic acid 
(FDA); CINQAERO® (reslizumab) 2.45 mg/ml; 0.12 mg/ml acetic acid; PRAXBIND® 
(idarucizumab) 2.95 mg/ml, 0.20 mg/ml acetic acid; DARZALEX® (daratumumab) 
2.96 mg/ml, 0.18 mg/ml acetic acid; CYLTEZO® (adalimumab) 3 mg/ml; 0.16 mg/ml 




(Non-amino acids BUFF) 1 
HUMIRA® (adalimumab, 50 mg/ml) 1.3 mg/ml citric acid, 0.3 mg/ml; ERBITUX® 
(cetuximab) 10 mM (1,92 mg/ml) citric acid; PORTRAZZA® (necitumumab) 10 mM 
(EMA), 2.55 mg/ml, 0.26 mg/ml citric acid (FDA); ZINPLAVA® (bezlotoxumab) 4.75 
mg/ml; 0.8 mg/ml citric acid, TALTZ® (ixekizumab) 5.11 mg/ml, 0.51 mg/ml citric acid; 
OPDIVO® (nivolumab) 5.88 mg/ml; BLITZIMA® (rituximab) 25 mM (7.35 mg/ml) 
tri-sodium dihydrate; RITEMVIA® (rituximab) 25 mM (7.35 mg/ml) tri-sodium 
dihydrate; RITUZENA® (rituximab) 25 mM (7.35 mg/ml) tri-sodium dihydrate; 
BLINCYTO® (blinatumomab) 1.20 mg/ml citric acid; 
EMPLICITI® (etoluzumab) 1.38 mg/ml; 0.20 mg/ml citric acid; 
BENLYSTA® (belimumab) 2.7 mg/ml, 0.16 mg/ml citric acid; 
ADCETRIS® (brentuximab vedotin) 20 mM*** (EMA); 5.6 




Excipient name Excipient quantitative composition of approved LIQUID antibody products Excipient quantitative composition of approved LYOPHILISED 
antibody products 
TRUXIMA® (rituximab) 25 mM (7.35 mg/ml) tri-sodium dihydrate; MABTHERA® 
(rituximab, 10 mg/ml) 7.35 mg/ml 
Sodium phosphate 
(Non-amino acids BUFF) 1 
TYSABRI® (natalizumab) 1.13 mg/ml monobasic monohydrate; 0.48 mg/ml dibasic 
heptahydrate; LEMTRADA® (alemtuzumab) 1.15 mg/ml dibasic dihydrate; HUMIRA® 
(adalimumab, 50 mg/ml) 1.53 mg/ml dibasic dihydrate, 0.85 mg/ml monobasic dihydrate; 
HYQVIA® (human normal Ig) 1.78 mg/ml dibasic; SOLIRIS® (eculizumab) 1.78 
mg/ml dibasic, 0.46 mg/ml monobasic; AVASTIN® (bevacizumab) 51 mM (EMA), 5.8 
mg/ml monobasic monohydrate, 1.2 mg/ml dibasic anhydrous (FDA); MVASI® 
(bevacizumab) 5.8 mg/ml monobasic monohydrate, 1.2 mg/ml dibasic anhydrous; 
ROACTEMRA® (tocilizumab, 20 mg/ml) 15 mM* 
SIMULECT® (basiliximab) 0.20 mg/ml; FLIXABI® (inflixabi) 
0.56 mg/ml monobasic monohydrate, 0.26 mg/ml dibasic 
heptahydrate; MYLOTARG® (gemtuzumab ozogamicin) 0.6 
mg/ml dibasic anhydrous, 0.1 mg/ml monobasic monohydrate; 
INFLECTRA® (infliximab) 0.61 mg/ml dibasic dihydrate; 0.22 
mg/ml monobasic monohydrate; REMSIMA® (infliximab) 0.61 
mg/ml dibasic dihydrate, 0.22 mg/ml monobasic monohydrate; 
REMICADE® (infliximab) 0.61 mg/ml dibasic  dihydrate, 0.22 
mg/ml monobasic monohydrate; NUCALA® (mepolizumab) 7.14 
mg/ml dibasic heptahydrate 
Sodium succinate 
(Non-amino acids BUFF) 1 
None KADCYLA® (trastuzumab emtansine) 10 mM (1.18 mg/ml) 
Tris 
(Non-amino acids BUFF) 1 
YERVOY® (ipilimumab) 3.15 mg/ml HCl BESPONSA® (inotuzumab ozogamicin) 2.4 mg/ml 
Arginine 
(Amino acids BUFF/S/BA) 2 
DUPIXENT® (dupilumab) 5.25 mg/ml HCl monohydrate; BENLYSTA® (belimumab) 
5.3 mg/ml HCl monohydrate; KEVZARA® (sarilumab) 7.84 mg/ml; ARZERRA® 
(ofatumumab) 10 mg/ml; HEMLIBRA® (emicizumab) 150 mM (26.13 mg/ml); 
XOLAIR® (omalizumab) 42.1 mg/ml HCl monohydrate  
ENTYVIO® (vedolizumab) 125 mM (26.34 mg/ml) HCl 
monohydrate 
Glycine 
(Amino acids BUFF/S/BA) 2 
SYNAGIS® (palivizumab) 0.1 mg/ml; ERBITUX® (cetuximab) 100 mM (7.5 mg/ml); 
LARTRUVO® (olaratumab) 7.5 mg/ml; CYRAMZA® (ramucirumab) 133 mM (9.98 
mg/ml); PORTRAZZA® (necitumumab) 133 mM (9.98 mg/ml); KIOVIG® (human 
normal Ig) 250 mM (18.77 mg/ml); HyQVIA® (human normal Ig) 250 mM (18.77 
mg/ml)  
SYNAGIS® (palivizumab) 0.2 mg/ml; SIMULECT® 
(basiliximab) 8 mg/ml 
Glutamic acid 
(Amino acids BUFF/S/BA) 2 
KYNTHEUM® (brodalumab) 4.33 mg/ml None 
Histidine 
(Amino acids BUFF/S/BA) 2 
SIMPONI® (golimumab) 0.87 mg/ml; PRALUENT® (alirocumab, 75 mg/ml) 8 mM 
(1.24 mg/ml); PRALUENT® (alirocumab, 100 mg/ml) 6 mM (0.93 mg/ml); 
STELARA® (ustekinumab, 90 mg/ml) 1 mg/ml; STELARA® (ustekinumab, 5 mg/ml) 
1.04 mg/ml HCl monohydrate, 0.77 mg/ml,; BENLYSTA® (belimumab) 1.2 mg/ml HCl 
monohydrate, 0.65 mg/ml; CYRAMZA® (ramucirumab) 10 mM (EMA), 1.22 mg/ml 
HCl monohydrate, 0.65 mg/ml (FDA); FASENRA® (benralizumab) 1.4 mg/ml, 2.3 
mg/ml HCl monohydrate; TREMFYA® (guselkumab) 1.5 mg/ml HCl monohydrate, 0.6 
mg/ml; KEYTRUDA® (pembrolizumab) 1.55 mg/ml; CRYSVITA® (burosumab) 1.55 
mg/ml; LARTRUVO® (olaratumab) 1.7 mg/ml HCl monohydrate, 0.3 mg/ml; 
ILARIS® (canakinumab) 2.1 mg/ml, 1.3 mg/ml HCl monohydrate; XOLAIR® 
(omalizumab) 2.34 mg/ml HCl monohydrate, 1.37 mg/ml; COSENTYX® 
(secukinumab) 20 mM (3.1 mg/ml); DUPIXENT® (dupilumab) 3.1 mg/ml; 
HEMLIBRA® (emicizumab) 20 mM (3.1 mg/ml); QARZIBA® (dinutuximab beta) 20 
mM (3.1 mg/ml); TECENTRIQ® (atezolizumab) 20 mM (3.1 mg/ml); KEVZARA® 
(sarilumab) 3.25 mg/ml; MABTHERA® (rituximab, 120 mg/ml) 3.47 mg/ml HCl 
monohydrate, 0.53 mg/ml;  SYNAGIS® (palivizumab) 3,9 mg/ml; PERJETA® 
(pertuzumab) 20 mM (4.28 mg/ml) acetate; LUCENTIS® (ranibizumab) 10 mM**; 
GAZYVARO® (obinutuzumab) 20 mM**; HERCEPTIN® (trastuzumab) 20 mM** 
HERCEPTIN® (trastuzumab) 0.48 mg/ml HCl monohydrate, 
0.31 mg/ml; HERZUMA® (trastuzumab) 0.48 mg/ml HCl 
monohydrate, 0.31 mg/ml; KANJINTI® (trastuzumab) 0.48 
mg/ml HCl monohydrate, 0.31 mg/ml; ONTRUZANT® 
(trastuzumab) 0.48 mg/ml HCl monohydrate, 0.31 mg/ml; 
SYLVANT® (siltuximab) 0.74 mg/ml; KEYTRUDA® 
(pembrolizumab) 1.55 mg/ml; XOLAIR® (omalizumab) 2 
mg/mL HCl monohydrate, 1.3 mg/mL;  ILARIS® (canakinumab) 
2.8 mg/ml, 1.7 mg/ml HCl monohydrate; COSENTYX® 
(secukinumab) 30 mM (4.66 mg/ml); SYNAGIS® (palivizumab) 
7.3 mg/ml; ENTYVIO® (vedolizumab) 50 mM (EMA), 4.6 





(Amino acids BUFF/S/BA) 2 
None BLINCYTO® (blinatumomab) 8.30 mg/ml HCl monohydrate 
Methionine 
(Amino acids BUFF/S/BA) 2 
STELARA® (ustekinumab, 5 mg/ml) 0.4 mg/ml; COSENTYX® (secukinumab) 5 mM 
(0.75 mg/ml); HERCEPTIN® (trastuzumab) 10 mM (1.49 mg/ml); CRYSVITA® 
(burosumab) 1.49 mg/ml;  MABTHERA® (rituximab, 120 mg/ml) 1.49 mg/ml  
None 
Proline 
(Amino acids BUFF/S/BA) 2 
KYNTHEUM® (brodalumab) 24 mg/ml; REPATHA® (evolocumab) 25 mg/ml; 
PRIVIGEN® (human normal Ig) 250 mM (28.78 mg/ml); HIZENTRA® (human 
normal Ig) 250 mM (28.78 mg/ml)  
None 
Dextran 
(Non-amino acids S/BA) 3 
None MYLOTARG® (gentuzumab ozogamicin) 9.1 mg/ml 
Human albumin 
(Non-amino acids S/BA) 3 
 




Excipient name Excipient quantitative composition of approved LIQUID antibody products Excipient quantitative composition of approved LYOPHILISED 
antibody products 
Mannitol 
(Non-amino acids S/BA) 3 
PORTRAZZA® (necitumumab) 50 mM (9.1 mg/ml); YERVOY® (ipilimumab) 10 
mg/ml; HUMIRA® (adalimumab, 50 mg/ml) 12 mg/ml; LARTRUVO® (olaratumab) 
13.7 mg/ml; DARZALEX® (daratumumab) 25.5 mg/ml; OPDIVO® (nivolumab) 30 
mg/ml; HUMIRA® (adalimumab, 100 mg/ml) 42 mg/ml; ILARIS® (canakinumab) 
49.2 mg/ml; BAVENCIO® (avelumab) 51 mg/ml 
SIMULECT® (basiliximab) 16 mg/ml; SYNAGIS® 
(palivizumab) 56.3 mg/ml 
Sorbitol 
(Non-amino acids S/BA) 3 
PRAXBIND® (idarucizumab) 40.08 mg/ml; SIMPONI® (golimumab) 41 mg/ml; 
CRYSVITA® (burosumab) 45.91 mg/ml;  XGEVA® (denosumab) 46 mg/ml; 
PROLIA® (denosumab) 47 mg/ml; FLEBOGAMMA DIF® (human normal Ig, 50 
mg/ml) 50 mg/ml 
None 
Sucrose 
(Non-amino acids S/BA) 3 
PERJETA® (pertuzumab) 120 mM (41.08 mg/ml); TECENTRIQ® (atezolizumab) 
120 mM (41.08 mg/ml); DUPIXENT® (dupilumab) 50 mg/ml; KEVZARA® 
(sarilumab) 50 mg/ml; QARZIBA® (dinutuximab beta) 50 mg/ml; ROACTEMRA® 
(tocilizumab, 20 mg/ml) 50 mg/ml; CINQAERO® (reslizumab) 70 mg/ml; 
KEYTRUDA® (pembrolizumab) 70 mg/ml; STELARA® (ustekinumab, 90 mg/ml) 76 
mg/ml; TREMFYA® (guselkumab) 79 mg/ml STELARA® (ustekinumab, 5 mg/ml) 85 
mg/ml; AMGEVITA® (adalimumab) 90 mg/ml; SOLYMBIC® (adalimumab) 90 
mg/ml; PRALUENT® (alirocumab) 100 mg/ml 
SIMULECT® (basiliximab) 4 mg/ml; MYLOTARG® 
(gemtuzumab ozogamicin) 15.5 mg/ml; SYLVANT® 
(siltuximab) 33.8 mg/ml; EMPLICITI® (etoluzumab) 42.5 
mg/ml; BESPONSA® (inotuzumab ozogamicin) 50 mg/ml; 
FLIXABI® (infliximab) 50 mg/ml; INFLECTRA® (infliximab) 
50 mg/ml; REMICADE® (infliximab) 50 mg/ml; REMSIMA® 
(infliximab) 50 mg/ml; KADCYLA® (trastuzumab emtansine) 
60 mg/ml; KEYTRUDA (pembrolizumab) 70 mg/ml; 
BENLYSTA® (belimumab) 80 mg/ml; ILARIS® 
(canakinumab) 92.4 mg/ml;  COSENTYX® (secukinumab) 270 
mM (EMA), 92.4 mg/ml (FDA); ENTYVIO® (vedolizumab) 100 
mg/ml; XOLAIR® (omalizumab) 104 mg/ml; NUCALA® 
(mepolizumab) 160 mg/ml 
Trehalose 
(Non-amino acids S/BA) 3 
OCREVUS® (ocrelizumab) 106 mM (EMA), 40 mg/ml (FDA); AVASTIN® 
(bevacizumab) 60 mg/ml; MVASI® (bevacizumab) 60 mg/ml; COSENTYX® 
(secukinumab) 200 mM (EMA), 75.67 mg/ml (FDA); HERCEPTIN® (trastuzumab) 
210 mM (71.88 mg/ml); MABTHERA® (rituximab, 120 mg/ml) 79,45 mg/ml; 
CYLTEZO® (adalimumab) 81.25 mg/ml; GAZYVARO® (obinutuzumab) 240 mM 
(82.15 mg/ml); FASENRA® (benralizumab) 95 mg/ml; LUCENTIS® (ranibizumab) 
100 mg/ml 
HERCEPTIN® (trastuzumab) 19.05 mg/ml; KANJINTI® 
(trastuzumab) 19.05 mg/ml; ONTRUZANT® (trastuzumab) 
19.05 mg/ml; BLINCYTO® (blinatumomab) 34.11 mg/ml; 




HIZENTRA® (human normal Ig) 0.02 mg/ml (EMA), 0.008-0.03 mg/ml (FDA);  
STELARA® (ustekinumab, 90 mg/ml) 0.04 mg/ml; BENLYSTA® (belimumab) 0.1 
mg/ml; ERBITUX® (cetuximab) 0.1 mg/ml; YERVOY® (ipilimumab) 0.1 mg/ml;  
LEMTRADA® (alemtuzumab) 0.1 mg/ml; CYRAMZA® (ramucirumab) 0.1 mg/ml;  
REPATHA® (evolocumab) 0.1 mg/ml; PORTRAZZA® (necitumumab) 0.1 mg/ml; 
SIMPONI® (golimumab)  0.16 mg/ml; ARZERRA® (ofatumumab) 0.2 mg/mL; 
COSENTYX® (secukinumab) 0.2 mg/ml; KEYTRUDA® (pembrolizumab) 0.2 mg/ml; 
OPDIVO® (nivolumab) 0.2 mg/ml; TYSABRI® (natalizumab) 0.2 mg/ml;  SOLIRIS® 
(eculizumab) 0.22 mg/ml; ZINPLAVA® (bezlotoxumab) 0.25 mg/ml; TALTZ® 
(ixekizumab) 0.3 mg/ml; ILARIS® (canakinumab) 0.4 mg/ml; STELARA® 
(ustekinumab, 5 mg/ml) 0.4 mg/ml; CRYSVITA® (burosumab) 0.5 mg/ml;  
ROACTEMRA® (tocilizumab, 20 mg/ml) 0.5 mg/ml; TREMFYA® (guselkumab) 0.5 
mg/ml; MABTHERA® (rituximab, 120 mg/ml) 0.6 mg/ml; MABTHERA® 
(rituximab, 10 mg/ml) 0.7 mg/ml; BLITZIMA® (rituximab) 0.7 mg/ml; RITEMVIA® 
(rituximab) 0.7 mg/ml; RITUZENA® (rituximab) 0.7 mg/ml; TRUXIMA® 
(rituximab) 0.7 mg/ml; AMGEVITA® (adalimumab) 1 mg/ml; CYLTEZO® 
(adalimumab) 1 mg/ml;  HUMIRA® (adalimumab, 50 mg/ml) 1 mg/ml; HUMIRA® 
(adalimumab, 100 mg/ml) 1 mg/ml; SOLYMBIC® (adalimumab) 1 mg/ml; 
DUPIXENT® (dupilumab) 2 mg/ml 
FLIXABI® (infliximab) 0.05 mg/ml; INFLECTRA® 
(infliximab) 0.05 mg/m; REMICADE® (infliximab) 0.05 mg/ml; 
REMSIMA® (infliximab) 0.05 mg/ml; BESPONSA® 
(inotuzumab ozogamicin) 0.1 mg/ml; SYLVANT® (siltuximab) 
0.16 mg/ml; ADCETRIS® (brentuximab vedotin) 0.2 mg/ml; 
KEYTRUDA® (pembrolizumab) 0.2 mg/ml; BLINCYTO® 
(blinatumomab) 0.23 mg/ml; EMPLICITI® (etoluzumab) 0.28 
mg/ml; BENLYSTA® (belimumab) 0.4 mg/ml; ILARIS® 
(canakinumab) 0.6 mg/ml; ENTYVIO® (vedolizumab) 0.6 
mg/ml; COSENTYX® (secukinumab) 0.6 mg/ml; NUCALA® 




FASENRA® (benralizumab) 0.06 mg/ml; LUCENTIS® (ranibizumab) 0.1 mg/ml; 
KYNTHEUM® (brodalumab) 0.1 mg/ml;  PROLIA® (denosumab) 0.1 mg/ml; 
PRALUENT® (alirocumab) 0.1 mg/ml; QARZIBA® (dinutuximab beta) 0.1 mg/ml; 
XGEVA® (denosumab) 0.1 mg/ml; OCREVUS® (ocrelizumab) 0.2 mg/ml; 
PERJETA® (pertuzumab) 0.2 mg/ml;  PRAXBIND® (idarucizumab) 0.2 mg/ml; 
LARTRUVO® (olaratumab) 0.2 mg/ml; AVASTIN® (bevacizumab) 0.4 mg/ml; 
DARZALEX® (daratumumab) 0.4 mg/ml;  HERCEPTIN® (trastuzumab) 0.4 mg/ml; 
TECENTRIQ® (atezolizumab) 0.4 mg/ml; MVASI® (bevacizumab) 0.4 mg/ml; 
XOLAIR® (omalizumab) 0.4 mg/ml; BAVENCIO® (avelumab) 0.5 mg/ml 
KEVZARA® (sarilumab) 2 mg/ml  
HERCEPTIN® (trastuzumab) 0.08 mg/ml; HERZUMA® 
(trastuzumab) 0.08 mg/ml; KANJINTI® (trastuzumab) 0.08 
mg/ml; ONTRUZANT® (trastuzumab) 0.08 mg/ml; 
KADCYLA® (trastuzumab emtansine) 0.2 mg/ml; XOLAIR® 
(omalizumab) 0.36 mg/ml 
Poloxamer 188 
(Surfactants)  













PORTRAZZA® (necitumumab) 40 mM (2.34 mg/ml);  LARTRUVO® (olaratumab) 
2.9 mg/ml; OPDIVO® (nivolumab) 2.92 mg/ml; ARZERRA® (ofatumumab) 2.98 
mg/mL; DARZALEX® (daratumumab) 3.5 mg/ml; CYRAMZA® (ramucirumab) (75 
mM) 4.38 mg/ml; VECTIBIX® (panitumumab) 5.8 mg/ml; ERBITUX® (cetuximab) 
100 mM (5.84 mg/ml); YERVOY® (ipilimumab) 5.85 mg/ml; HUMIRA® 
(adalimumab, 50 mg/ml) 6.18 mg/ml; BENLYSTA® (belimumab) 6.7 mg/ml; 
CIMZIA® (certolizumab pegol) 7.31 mg/ml;  LEMTRADA® (alemtuzumab) 8 mg/ml; 
TYSABRI® (natalizumab) 8.2 mg/ml; HYQVIA® (human normal Ig) 8.5 mg/ml; 
SOLIRIS® (eculizumab) 8.77 mg/ml; ZINPLAVA® (bezlotoxumab) 8.77 mg/ml; 
MABTHERA® (rituximab, 10 mg/ml) 9 mg/ml; TRUXIMA® (rituximab) 154 mM (9 
mg/ml); BLITZIMA® (rituximab) 154 mM (9 mg/ml); RITEMVIA® (rituximab) 154 
mM (9 mg/ml); RITUZENA® (rituximab) 154 mM (9 mg/ml); TALTZ® (ixekizumab) 
11.69 mg/ml 
SIMULECT® (basiliximab) 0.32 mg/ml; BESPONSA® 
(inotuzumab ozogamicin) 0.6 mg/ml MYLOTARG® 
(gemtuzumab ozogamicin) 5.8 mg/ml 
Calcium chloride 
(Other excipients) 
HYQVIA® (human normal Ig) 0.4 mg/ml None 
EDTA 
(Other excipients)  
STELARA® (ustekinumab, 5 mg/ml) 0.02 mg/ml; ARZERRA® (ofatumumab) 0.02 




(Other excipients)  
OPDIVO® (nivolumab) 0.01 mg/ml; ZINPLAVA® (bezlotoxumab) 0.01 mg/ml; 




(Other excipients)  
MABTHERA (rituximab, 120 mg/ml) 2000 units/ml; HERCEPTIN® (trastuzumab) 
2000 units/ml; HYQVIA® (human normal Ig) 160 units/ml 
None 
 
*Disodium phosphate dodecahydrate/Sodium dihydrogen phosphate dihydrate; **Histidine/Histidine-HCl; 
***Sodium citrate/Citric acid  
 
1) Non-amino acids BUFF (buffers); 2) Amino acids BUFF/S/BA (buffers/stabilisers/bulking agents); 3) Non-
amino acids S/BA (stabilisers/bulking agents) 
     
   Note: The function of these excipients as bulking agents is only relevant for lyophilised products 
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